Stockreport

Kezar Life Sciences Announces Cessation of Enrollment and Dosing in the Phase 2b PALIZADE Trial of Zetomipzomib in Active Lupus Nephritis Patients

Kezar Life Sciences, Inc.  (KZR) 
Last kezar life sciences, inc. earnings: 8/7 04:05 pm Check Earnings Report
PDF SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing a novel small molecule to tr [Read more]